About Benitec Biopharma Limited (NASDAQ:BNTC)
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Healthcare
- Symbol: NASDAQ:BNTC
- CUSIP: N/A
- Web: www.benitec.com
- Current Ratio: 19.88%
- Quick Ratio: 19.88%
Sales & Book Value:
- Annual Sales: $8.36 million
- Price / Sales: 3.20
- Book Value: $1.58 per share
- Price / Book: 1.65
- Net Income: $-4,280,000.00
- Net Margins: -50.76%
- Return on Equity: -26.97%
- Return on Assets: -25.55%
- Employees: 18
- Outstanding Shares: 10,260,000
Frequently Asked Questions for Benitec Biopharma Limited (NASDAQ:BNTC)
What is Benitec Biopharma Limited's stock symbol?
Benitec Biopharma Limited trades on the NASDAQ under the ticker symbol "BNTC."
When will Benitec Biopharma Limited make its next earnings announcement?
Who are some of Benitec Biopharma Limited's key competitors?
Some companies that are related to Benitec Biopharma Limited include OvaScience (OVAS), Prima BioMed Ltd (PBMD), Ohr Pharmaceuticals (OHRP), Oncobiologics (ONS), AEterna Zentaris (AEZS), Bio-Path Holdings (BPTH), Scancell Holdings Plc (SCLP), Genocea Biosciences (GNCA), Caladrius Biosciences (CLBS), Prana Biotechnology Ltd (PRAN), Cleveland BioLabs (CBLI), Can Fite Biopharma Ltd (CANF), Fibrocell Science (FCSC), Repros Therapeutics (RPRX), OncoGenex Pharmaceuticals (ACHV), Burcon NutraScience Corp (BUR), RXi Pharmaceuticals Corporation (RXII) and Synairgen plc (SNG).
Who are Benitec Biopharma Limited's key executives?
Benitec Biopharma Limited's management team includes the folowing people:
- Gregory West, Chief Executive Officer, Company Secretary
- Bryan Dulhunty, Chief Financial Officer
- Clifford Michael Holloway, Chief Business and Operating Officer (Age 57)
- Michael Graham, Chief Scientific Officer
- Jerel A. Banks M.D., Ph.D., Non-Executive Chairman of the Board
- Kevin Buchi CPA, Director
- Megan Joan Boston, Non-Executive Director
- Peter Damian Francis, Non-Executive Director
When did Benitec Biopharma Limited IPO?
(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.
How do I buy Benitec Biopharma Limited stock?
Shares of Benitec Biopharma Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Benitec Biopharma Limited's stock price today?
One share of Benitec Biopharma Limited stock can currently be purchased for approximately $2.61.
How big of a company is Benitec Biopharma Limited?
Benitec Biopharma Limited has a market capitalization of $26.77 million and generates $8.36 million in revenue each year. Benitec Biopharma Limited employs 18 workers across the globe.
How can I contact Benitec Biopharma Limited?
Benitec Biopharma Limited's mailing address is SE 1201 99 Mount St, NORTH SYDNEY, NSW 2060, Australia. The biotechnology company can be reached via phone at +61-2-95556986 or via email at [email protected]
MarketBeat Community Rating for Benitec Biopharma Limited (BNTC)MarketBeat's community ratings are surveys of what our community members think about Benitec Biopharma Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Benitec Biopharma Limited (NASDAQ:BNTC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Benitec Biopharma Limited (NASDAQ:BNTC)
Analysts' Ratings History for Benitec Biopharma Limited (NASDAQ:BNTC)
(Data available from 11/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/30/2017||Maxim Group||Reiterated Rating||Hold||Medium|
Earnings History for Benitec Biopharma Limited (NASDAQ:BNTC)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Benitec Biopharma Limited (NASDAQ:BNTC)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Benitec Biopharma Limited (NASDAQ:BNTC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Benitec Biopharma Limited (NASDAQ BNTC)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Benitec Biopharma Limited (NASDAQ BNTC)
Financials are not available for this stock.
Benitec Biopharma Limited (NASDAQ BNTC) Chart for Wednesday, November, 22, 2017